GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Schott Pharma AG & CO KGaA (CHIX:1SXPd) » Definitions » EV-to-FCF

Schott Pharma AG KGaA (CHIX:1SXPD) EV-to-FCF : 79.50 (As of Mar. 14, 2025)


View and export this data going back to 2024. Start your Free Trial

What is Schott Pharma AG KGaA EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Schott Pharma AG KGaA's Enterprise Value is €3,637.0 Mil. Schott Pharma AG KGaA's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2024 was €45.7 Mil. Therefore, Schott Pharma AG KGaA's EV-to-FCF for today is 79.50.

The historical rank and industry rank for Schott Pharma AG KGaA's EV-to-FCF or its related term are showing as below:

CHIX:1SXPd' s EV-to-FCF Range Over the Past 10 Years
Min: -1724.33   Med: 133.73   Max: 833.69
Current: 78.71

During the past 5 years, the highest EV-to-FCF of Schott Pharma AG KGaA was 833.69. The lowest was -1724.33. And the median was 133.73.

CHIX:1SXPd's EV-to-FCF is ranked worse than
83.24% of 376 companies
in the Medical Devices & Instruments industry
Industry Median: 27.96 vs CHIX:1SXPd: 78.71

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

As of today (2025-03-14), Schott Pharma AG KGaA's stock price is €23.72. Schott Pharma AG KGaA's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 was €0.890. Therefore, Schott Pharma AG KGaA's PE Ratio (TTM) for today is 26.65.


Schott Pharma AG KGaA EV-to-FCF Historical Data

The historical data trend for Schott Pharma AG KGaA's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Schott Pharma AG KGaA EV-to-FCF Chart

Schott Pharma AG KGaA Annual Data
Trend Sep20 Sep21 Sep22 Sep23 Sep24
EV-to-FCF
- - - 785.52 58.47

Schott Pharma AG KGaA Quarterly Data
Sep20 Sep21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 139.00 -1,734.78 212.93 58.47 82.36

Competitive Comparison of Schott Pharma AG KGaA's EV-to-FCF

For the Medical Instruments & Supplies subindustry, Schott Pharma AG KGaA's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Schott Pharma AG KGaA's EV-to-FCF Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Schott Pharma AG KGaA's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Schott Pharma AG KGaA's EV-to-FCF falls into.



Schott Pharma AG KGaA EV-to-FCF Calculation

Schott Pharma AG KGaA's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=3636.952/45.746
=79.50

Schott Pharma AG KGaA's current Enterprise Value is €3,637.0 Mil.
Schott Pharma AG KGaA's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €45.7 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Schott Pharma AG KGaA  (CHIX:1SXPd) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Schott Pharma AG KGaA's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=23.72/0.890
=26.65

Schott Pharma AG KGaA's share price for today is €23.72.
Schott Pharma AG KGaA's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.890.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Schott Pharma AG KGaA EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Schott Pharma AG KGaA's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Schott Pharma AG KGaA Business Description

Traded in Other Exchanges
Address
Hattenbergstrasse 10, Mainz, RP, DEU, 55122
Schott Pharma AG & CO KGaA caters to the pharma, biotech and life science industry by providing containment solutions and delivery systems for injectable drugs. Its segments include; Drug Containment Solutions (DCS) and Drug Delivery Systems (DDS). The majority of the revenue is generated from Drug Containment Solutions segment which includes products like vials, cartridges and ampoules for safe drug containment. Geographically, the company generates revenue from Europe, Middle East, Africa (EMEA), Asia and South Pacific, North America and South America.

Schott Pharma AG KGaA Headlines

No Headlines